|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Haggstrom L, Chan WY, Nagrial A, Chantrill
LA, Sim HW, Yip D and Chin V: Chemotherapy and radiotherapy for
advanced pancreatic cancer. Cochrane Database Syst Rev.
12(CD011044)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Riely GJ, Wood DE, Aisner DL, Loo BW Jr,
Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, et
al: NCCN guidelines® insights: Non-small cell lung
cancer, version 7.2025. J Natl Compr Canc Netw. 23:354–362.
2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gao S, Ye K, Zhang Z, Wang W, Li J, Xu T
and Tan H: Polysaccharides of Pseudostellaria heterophylla (Miq.)
Pax ex Pax et Hoffm: Extraction, purification, structural
characteristics, pharmacological activities, and structure-activity
relationships: A review. Int J Biol Macromol.
330(148082)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gao S, Zhang Z, Ye K, Wang W, Li J, Xu T
and Tan H: Comprehensive characterization of Rubus idaeus L.
Polysaccharides: Extraction, purification, structural diversity,
biological efficacy, and structure-activity relationships. J
Ethnopharmacol. 355(120677)2026.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Jiang Y, Wang C, Zu C, Rong X, Yu Q and
Jiang J: Synergistic potential of nanomedicine in prostate cancer
immunotherapy: Breakthroughs and prospects. Int J Nanomedicine.
19:9459–9486. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Singh N, Hocking AM and Buckner JH:
Immune-related adverse events after immune check point inhibitors:
Understanding the intersection with autoimmunity. Immunol Rev.
318:81–88. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zimmerman JL and Shen MC: Rhabdomyolysis.
Chest. 144:1058–1065. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jayan A, Mammen AL and Suarez-Almazor ME:
Immune checkpoint inhibitor-induced myositis. Rheum Dis Clin North
Am. 50:281–290. 2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Plomp L, Chassepot H, Psimaras D,
Maisonobe T, Mensi E, Leonard-Louis S, Plu I, Rozes A, Tubach F,
Touat M, et al: Features of myositis and myasthenia gravis in
patients treated with immune checkpoint inhibitors: A multicentric,
retrospective cohort study. Lancet Reg Health Eur.
50(101192)2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Neppl C, Keller MD, Scherz A, Dorn P,
Schmid RA, Zlobec I and Berezowska S: Comparison of the 7 and 8th
edition of the UICC/AJCC TNM staging system in primary resected
squamous cell carcinomas of the lung-A single center analysis of
354 cases. Front Med (Lausanne). 6(196)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Weng C, Ding Z, Zhou Y, Yang Q, Xue L,
Zhang L, Wang G and Liu Z: Clinical characteristics of
dermatomyositis with interstitial lung disease: A retrospective
case-control study. Rheumatol Ther. 10:635–648. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li JX and Cummins CL: Fresh insights into
glucocorticoid-induced diabetes mellitus and new therapeutic
directions. Nat Rev Endocrinol. 18:540–557. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Klecha AJ, Barreiro Arcos ML, Frick L,
Genaro AM and Cremaschi G: Immune-endocrine interactions in
autoimmune thyroid diseases. Neuroimmunomodulation. 15:68–75.
2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baghi MA, Sirajudeen J, Naushad VA, Alarbi
KS and Benshaban N: Severe hypothyroidism-induced rhabdomyolysis: A
case report. Clin Case Rep. 9(e05107)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bloise FF, Cordeiro A and Ortiga-Carvalho
TM: Role of thyroid hormone in skeletal muscle physiology. J
Endocrinol. 236:R57–R68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dentice M, Ambrosio R, Damiano V, Sibilio
A, Luongo C, Guardiola O, Yennek S, Zordan P, Minchiotti G, Colao
A, et al: Intracellular inactivation of thyroid hormone is a
survival mechanism for muscle stem cell proliferation and lineage
progression. Cell Metab. 20:1038–1048. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aguiari P, Villani V, Liu KY, Brent GA,
Perin L and Milanesi A: 8670 Hypothyroidism impairs skeletal muscle
regeneration after injury. J Endocr Soc. 8 (Suppl
1)(bvae163.1812)2024.
|
|
19
|
Govindan R, Bogart J, Stinchcombe T, Wang
X, Hodgson L, Kratzke R, Garst J, Brotherton T and Vokes EE:
Randomized phase II study of pemetrexed, carboplatin, and thoracic
radiation with or without cetuximab in patients with locally
advanced unresectable non-small-cell lung cancer: Cancer and
Leukemia Group B trial 30407. J Clin Oncol. 29:3120–3125.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang M, Zhang G, Niu Y, Zhang G, Ji Y,
Yan X, Zhang X, Wang Q, Jing X, Wang J, et al: Sintilimab with two
cycles of chemotherapy for the treatment of advanced squamous
non-small cell lung cancer: A phase 2 clinical trial. Nat Commun.
15(1512)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen
G, Zhang L, Huang D, Cang S, Yang Z, et al: Sintilimab plus
platinum and gemcitabine as first-line treatment for advanced or
metastatic squamous NSCLC: Results from a randomized, double-blind,
phase 3 trial (ORIENT-12). J Thorac Oncol. 16:1501–1511.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yasuda Y, Iwama S, Sugiyama D, Okuji T,
Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, et al:
CD4+ T cells are essential for the development of
destructive thyroiditis induced by anti-PD-1 antibody in
thyroglobulin-immunized mice. Sci Transl Med.
13(eabb7495)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Merino-Vico A, Kocyigit M, Frazzei G,
Landman L, Boon L, van Leeuwen EM, Lundberg IE, van der Kooi AJ,
Raaphorst J, van Hamburg JP and Tas SW: Modulating IL-21-driven B
cell responses in idiopathic inflammatory myopathies via inhibition
of the JAK/STAT pathway. Arthritis Res Ther. 27(76)2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kuchroo JR, Hafler DA, Sharpe AH and Lucca
LE: The double-edged sword: Harnessing PD-1 blockade in tumor and
autoimmunity. Sci Immunol. 6(eabf4034)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Pirkmajer S and Chibalin AV: Na,K-ATPase
regulation in skeletal muscle. Am J Physiol Endocrinol Metab.
311:E1–E31. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nappi A, Moriello C, Morgante M, Fusco F,
Crocetto F and Miro C: Effects of thyroid hormones in skeletal
muscle protein turnover. J Basic Clin Physiol Pharmacol.
35:253–264. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Beecher G, Pinal-Fernandez I, Mammen AL
and Liewluck T: Immune checkpoint inhibitor myopathy: The
double-edged sword of cancer immunotherapy. Neurology.
103(e210031)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Matas-García A, Milisenda JC,
Selva-O'Callaghan A, Prieto-González S, Padrosa J, Cabrera C,
Reguart N, Castrejón N, Solé M, Ros J, et al: Emerging PD-1 and
PD-1L inhibitors-associated myopathy with a characteristic
histopathological pattern. Autoimmun Rev. 19(102455)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hebert JF, Burfeind KG, Malinoski D and
Hutchens MP: Molecular mechanisms of rhabdomyolysis-induced kidney
injury: From bench to bedside. Kidney Int Rep. 8:17–29.
2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sundarrajan C, Bhai S and Dimachkie MM:
Immune checkpoint inhibitor-related myositis: From pathophysiology
to treatment. Clin Exp Rheumatol. 41:379–385. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shikano K, Kaneko K, Kaburaki K, Isobe K,
Kawabe K, Homma S, Kawai S and Nanki T: Nivolumab-induced
anti-aminoacyl-tRNA synthetase antibody-positive polymyositis
complicated by interstitial pneumonia in a patient with lung
adenocarcinoma. Scand J Rheumatol. 49:82–83. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Osaki M, Tachikawa R, Ohira J, Hara S and
Tomii K: Anti-transcriptional intermediary factor 1-γ
antibody-positive dermatomyositis induced by nivolumab for lung
adenocarcinoma: A case report. Invest New Drugs. 39:251–255.
2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pilia AM, Salvati L, Guidolin A, Mazzoni
F, Antonuzzo L, Parronchi P and Liotta F: Pembrolizumab-associated
anti-MDA5 dermatomyositis in a patient with lung cancer: A first
case report. Swiss Med Wkly. 154(3513)2024.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Lundberg IE, Tjärnlund A, Bottai M, Werth
VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ,
Liang MH, et al: 2017 European league against rheumatism/American
college of rheumatology classification criteria for adult and
juvenile idiopathic inflammatory myopathies and their major
subgroups. Ann Rheum Dis. 76:1955–1964. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kirou RA, Pinal-Fernandez I,
Casal-Dominguez M, Pak K, Preusse C, Dari D, Del Orso S, Naz F,
Islam S, Gutierrez-Cruz G, et al: Distinct cytokine and cytokine
receptor expression patterns characterize different forms of
myositis. medRxiv [Preprint]: Feb 21, 2025 (Epub ahead of
print).
|
|
37
|
Iwama S, Kobayashi T and Arima H:
Management, biomarkers and prognosis in people developing
endocrinopathies associated with immune checkpoint inhibitors. Nat
Rev Endocrinol. 21:289–300. 2025.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yamauchi I and Yabe D: Best practices in
the management of thyroid dysfunction induced by immune checkpoint
inhibitors. Eur Thyroid J. 14(e240328)2025.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sánchez-Camacho A, Torres-Zurita A,
Gallego-López L, Hernández-Pacheco R, Silva-Romeiro S, Álamo de la
Gala MDC, Peral-Gutiérrez de Ceballos E and de la Cruz-Merino L:
Management of immune-related myocarditis, myositis and myasthenia
gravis (MMM) overlap syndrome: A single institution case series and
literature review. Front Immunol. 16(1597259)2025.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
